WO1998041514A1 - Procede de production de derives de quinazoline - Google Patents
Procede de production de derives de quinazoline Download PDFInfo
- Publication number
- WO1998041514A1 WO1998041514A1 PCT/JP1998/001111 JP9801111W WO9841514A1 WO 1998041514 A1 WO1998041514 A1 WO 1998041514A1 JP 9801111 W JP9801111 W JP 9801111W WO 9841514 A1 WO9841514 A1 WO 9841514A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- general formula
- compound
- compound represented
- carboxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
Definitions
- the present invention relates to a novel method for producing the following quinazoline derivative (I) useful as a raw material for the quinazoline derivative described in Japanese Patent Application Laid-Open No. 62-96476. Useful in the pharmaceutical industry. Background art
- the present invention provides a novel and more industrial production method of the quinazoline derivative (I). Disclosure of the invention
- the present invention has the general formula:
- R 1 is hydrogen or halogen
- R 2 is carboxy or protected carboxy
- A is lower alkylene
- the method for producing the quinazoline derivative (I) or a salt thereof according to the present invention is as follows.
- the inventors of the present invention have found that the compound (II) is reacted with a silylating agent, then the compound (III), Quinazoli can be produced inexpensively, safely and easily, and at a high yield.
- the present inventors have found that a derivative (I) can be obtained and completed the present invention.
- the salt of the quinazoline derivative (I) obtained in the present invention include alkali metal salts such as lithium salt, sodium salt and potassium salt, and alkali salts such as calcium salt and magnesium salt.
- Salts with inorganic bases such as earth metal salts and ammonium salts, such as triethylamine salt, pyridine salt, picolinate salt, ethanolamine salt, triethanolamine salt, Salts with bases such as salts with organic bases such as organic amine salts such as dicyclohexylamine salt, N, N * -dibenzylethylenediamine salt, for example, hydrochloride, hydrobromide , Sulfates, phosphates and other inorganic acid addition salts, such as formate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, toluenesulfone Organic acids such as acid salts Salts with Yo I Do not acid of salting, and the like.
- bases such as salts with organic bases such as organic amine salts such as dicyclohexylamine salt, N, N * -dibenzylethylenediamine salt, for example, hydroch
- Suitable "halogens” include, for example, fluorine, chlorine, bromine and iodine.
- Suitable “substituted silyl” include mono (or di or tri) substituted silyl.
- Suitable substituents in “mono (or di- or tri-substituted) silyl” include, for example, lower alkyl, lower alkenyl, aryl, one or more suitable substituents. And al (lower) alkyl.
- Suitable "lower alkyl” in the appropriate “lower alkyl” and “ar (lower) alkyl optionally having one or more suitable substituents” is methyl, ethyl, propyl And straight or branched chain alkyls such as isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl and the like.
- Suitable “lower alkenyl” include vinyl, aryl, isopropenyl, 1 or 2 or 3 —butenyl, 1 or 2 or 3 or 4 —pentenyl, 1 or 2 or 3 or 4 or Examples thereof include straight-chain or branched-chain alkenyl having 2 to 6 carbon atoms such as 5-hexenyl.
- Suitable "aryl” in the appropriate “aryl” and “ar (lower) alkyl optionally having one or more suitable substituents” include phenyl, naphthyl and the like. No.
- Suitable substituents in “anor (lower) alkyl optionally having one or more suitable substituents” include mono (or di or di or B) halo (lower) alkyl (for example, chloromethyl, bromomethyl, chloropropinole, 1,2-dichloroethyl, 1,2-dibromoethyl, 2,2-dichloroethyl, trifcleolo Methinole, 1,2,2—trichloroethyl, etc.), lower alkoxy (eg methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentyloxy, isopentyloxy, hexyloxy, etc.) , Halogen (eg, fluorine, chlorine, bromine, iodine, etc.), lower alkyl (For example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pen
- Suitable "protected carboxy” include esterified carboxy such as lower alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonole, isopropoxycanoleboninole, butoxycanoleboninole, t-butoxycarbonyl, etc.), mono (or di- or tri) phenyl (lower) alkoxycarbonyl (eg, benzyloxycarbinole, 4-nitrobenzyloxy) which may have a nitrogen atom Shikanoreboninore, Hue phenethyl Honoré oxy Kano repo two Honoré, Benzuhi drill Ruo alkoxycarbonyl, preparative pentaerythrityl O alkoxycarbonyl, etc.), etc., and examples correct favored their caries Chisa we C i ⁇ C 4 alkoxycarbonyl And the most favorable one is ethoxy Is Reboninore.
- esterified carboxy such
- Suitable "lower alkylenes" include, for example, methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexanemethylene, methinomethylene, ethylethylene, propylene , include those of Do straight chain or branched if Yo etc. obtained, eg correct favored these caries Chisa we Ri C ⁇ C 4 alkylene der, most preferred correct ones by its in methylene is there.
- the quinazoline derivative (I) or a salt thereof is a compound (II) or Alternatively, the compound can be produced by reacting a silylating agent with a silylating agent and then the compound (III) or a salt thereof and, if necessary, desilylating the compound.
- Suitable salts of the compound (II) include salts with acids as exemplified for the compound (I).
- Suitable salts of compound (III) include salts with bases as exemplified for compound (I).
- silylating agent used in the present invention examples include hexametyldisilazane, trimethylchlorsilane, N, 0-bis (trimethylsilicure) acetamide, and hexametildiyl.
- the reaction with the silylating agent is usually carried out in a conventional solvent such as toluene, tetrahydrofuran, dioxane, dichloromethane or the like which does not adversely affect the reaction.
- a conventional solvent such as toluene, tetrahydrofuran, dioxane, dichloromethane or the like which does not adversely affect the reaction.
- the reaction temperature is not particularly limited, it is usually carried out under cooling or under heating.
- reaction with the compound (III) or a salt thereof is preferably performed in the presence of a catalyst.
- Suitable catalysts include, for example, bromide [eg, Br—Y—R 3 , wherein R 3 is carboxy or protected carboxy (preferably esterified carboxy, more preferably Is lower alkoxycarbonyl, most preferably ethoxycarbon, Y is lower alkylene (preferably Ci-C4alkylene) Or a salt thereof, Br-R 4 wherein R 4 is a substituted or unsubstituted silyl (preferably tri-substituted) A silyl, more preferably tri (lower) alkylsilyl, most preferably trimethylsilyl), or a salt thereof, MX 1 [where M is an alkali metal ( X 1 preferably represents bromine or iodine (preferably bromine), etc., and the like, and the like, and X 1 is preferably bromine or iodine (preferably bromine).
- bromide eg, Br—Y—R 3 , wherein R 3 is carboxy or protected carboxy (preferably esterified carboxy
- the amount of the catalyst is preferably about 0.1 to 0.5 mol, more preferably about 0.1 to 0.4 mol, per 1 mol of compound (II) or a salt thereof.
- This reaction is carried out in the presence or absence of a conventional solvent that does not adversely affect the reaction, but has a large relative permittivity (preferably, a relative permittivity ⁇ of 5 or more).
- a conventional solvent that does not adversely affect the reaction, but has a large relative permittivity (preferably, a relative permittivity ⁇ of 5 or more).
- the most preferred solvent is propylene carbonate.
- the reaction temperature is not particularly limited, it is usually carried out under heating or heating, preferably at about 80 ° C or higher, more preferably at about 90 ° C to 160 ° C, Most preferably, it is performed at about 100 ° C to 150 ° C.
- the reaction is carried out by a conventional method such as hydrolysis or alcoholysis.
- the production of the quinazoline derivative (I) or a salt thereof from the compound (II) or a salt thereof according to the present invention involves isolation and purification during the process. Can be performed continuously.
- the reaction mixture was cooled to 0 to 20 ° C., stirred at the same temperature for 1 hour, separated from the crystals, and the obtained wet crystals were added with water (280 ml), methanol (280 ml), concentrated hydrochloric acid (26.8 g) was added dropwise at an internal temperature of 30 to 35 ° C over about 30 minutes, and the reaction was carried out at the same temperature for 2 hours.
- the crystals were filtered, washed with water, and dried to obtain 7-chloro-2,4-dioxo-1,2,3,4-tetrahydroquinazoline (43.58 g).
- Example 2 The same operation as in Example 1 was performed on 7-chloro-2,4-dioxo-1,2,3,4—tetrahydroquinazoline (10 g) to obtain 7-chloro-2,4-bis ( A concentrated residue containing (trimethylsilinoleoxy) quinazoline was obtained. To this residue After adding Chinole (20 ml) and reacting at an internal temperature of 140-150 ° C for 29 hours, the reaction mixture was cooled to 70 ° C or less, and ethyl acetate (20 ml) was added.
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/380,609 US6344559B1 (en) | 1997-03-17 | 1998-03-17 | Process for producing quinazoline derivatives |
EP98907257A EP1010695A1 (en) | 1997-03-17 | 1998-03-17 | Process for producing quinazoline derivatives |
CA002283514A CA2283514A1 (en) | 1997-03-17 | 1998-03-17 | Process for producing quinazoline derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9/62617 | 1997-03-17 | ||
JP6261797 | 1997-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998041514A1 true WO1998041514A1 (fr) | 1998-09-24 |
Family
ID=13205469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/001111 WO1998041514A1 (fr) | 1997-03-17 | 1998-03-17 | Procede de production de derives de quinazoline |
Country Status (5)
Country | Link |
---|---|
US (1) | US6344559B1 (ja) |
EP (1) | EP1010695A1 (ja) |
KR (1) | KR20000075934A (ja) |
CA (1) | CA2283514A1 (ja) |
WO (1) | WO1998041514A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002026719A1 (fr) * | 2000-09-26 | 2002-04-04 | Fujisawa Pharmaceutical Co., Ltd. | Procede servant a preparer des quinazolines 1-substituees |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2237366A1 (en) * | 1997-05-13 | 1998-11-13 | Sumitomo Chemical Company, Limited | A process for producing 1-substituted tetrahydroquinazolines |
EP2686305B1 (en) | 2011-03-14 | 2020-09-16 | Impact Therapeutics, Inc. | Quinazolinediones and their use |
TWI527800B (zh) | 2011-04-01 | 2016-04-01 | 南京英派藥業有限公司 | 作為聚(二磷酸腺苷酸-核醣)聚合酶(parp)之抑制劑之1-(芳基甲基)喹唑啉-2,4(1h,3h)-二酮及其應用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6425767A (en) * | 1987-04-03 | 1989-01-27 | Fujisawa Pharmaceutical Co | Production of quinazoline derivative or salt thereof |
JPH09194466A (ja) * | 1995-11-14 | 1997-07-29 | Sumitomo Chem Co Ltd | 1−置換テトラヒドロキナゾリン類の製造方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994542A (en) | 1995-11-14 | 1999-11-30 | Sumitomo Chemical Company, Limited | Process for producing 1-substituted tetrahydroquinazolines |
CA2190236C (en) | 1995-11-14 | 2000-01-25 | Shinji Nishii | Process for producing 1-substituted tetrahydroquinazolines |
CA2237366A1 (en) * | 1997-05-13 | 1998-11-13 | Sumitomo Chemical Company, Limited | A process for producing 1-substituted tetrahydroquinazolines |
-
1998
- 1998-03-17 CA CA002283514A patent/CA2283514A1/en not_active Abandoned
- 1998-03-17 EP EP98907257A patent/EP1010695A1/en not_active Withdrawn
- 1998-03-17 US US09/380,609 patent/US6344559B1/en not_active Expired - Fee Related
- 1998-03-17 KR KR1019997008015A patent/KR20000075934A/ko not_active Application Discontinuation
- 1998-03-17 WO PCT/JP1998/001111 patent/WO1998041514A1/ja not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6425767A (en) * | 1987-04-03 | 1989-01-27 | Fujisawa Pharmaceutical Co | Production of quinazoline derivative or salt thereof |
JPH09194466A (ja) * | 1995-11-14 | 1997-07-29 | Sumitomo Chem Co Ltd | 1−置換テトラヒドロキナゾリン類の製造方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1010695A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002026719A1 (fr) * | 2000-09-26 | 2002-04-04 | Fujisawa Pharmaceutical Co., Ltd. | Procede servant a preparer des quinazolines 1-substituees |
Also Published As
Publication number | Publication date |
---|---|
EP1010695A4 (en) | 2000-06-21 |
CA2283514A1 (en) | 1998-09-24 |
EP1010695A1 (en) | 2000-06-21 |
KR20000075934A (ko) | 2000-12-26 |
US6344559B1 (en) | 2002-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0662650B2 (ja) | チロシンキナーゼ阻害剤としてのベンジルホスホン酸 | |
KR20010030712A (ko) | 항엽산제 제조에 유용한 방법 및 중간체 | |
US6825345B2 (en) | Process for purification of a cephalosporin derivative | |
WO1998041514A1 (fr) | Procede de production de derives de quinazoline | |
US5389637A (en) | 2-formylamino-6-halogenopurine | |
JPH07316159A (ja) | 葉酸の製造法 | |
KR100430575B1 (ko) | 란소프라졸 및 그 중간체의 제조방법 | |
EP0259663B1 (en) | Process for producing tetrafluorophihalic acid | |
US4894457A (en) | 7-bromo-beta-carboline compound and method for producing same | |
US4438276A (en) | Process for synthesizing N-isopropyl-N'-o-carbomethoxyphenylsulphamide | |
KR950001026B1 (ko) | 페니실란산 유도체의 개선된 제조방법 | |
US4159378A (en) | Method for the preparation of derivatives of uracil | |
JP2608761B2 (ja) | 7−ブロモ−β−カルボリン誘導体の製造方法およびその中間体 | |
US4301072A (en) | Process for preparing aminopenicillins | |
JP2001114767A (ja) | ピリミジン化合物の製造方法、およびその中間体の製造方法 | |
US4231954A (en) | Dane salt and process for preparing aminopenicillins therefrom | |
JP3355797B2 (ja) | α位に塩素原子を有するピリジン類の製造方法 | |
JPH0469380A (ja) | 塩素化ピラゾールカルボン酸誘導体の製造方法 | |
JPH0789973A (ja) | (ジメトキシホスフイニル)[[1,1−ジメチルエチル)ジメチルシリル]オキシ]酢酸(4−ニトロフエニル)メチルエステルの改良された合成方法 | |
CA1083582A (en) | Process for the preparation of halogenomethylene- indoxyls | |
JPH07206821A (ja) | α位に塩素原子を有するピリジン類の製造方法 | |
US6992231B2 (en) | Method for the preparation of α,α, α′,α′-tetrachloro-p-xylene | |
KR910001999B1 (ko) | 벤조일 말로네이트 유도체의 제조방법 | |
KR870000725B1 (ko) | 세펨 화합물의 제조방법 | |
JPS62267267A (ja) | ピラゾ−ル誘導体およびその製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
CFP | Corrected version of a pamphlet front page |
Free format text: PUBLISHED ABSTRACT AND FIGURE REPLACED BY CORRECTED ABSTRACT AND FIGURE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1019997008015 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2283514 Country of ref document: CA Ref country code: CA Ref document number: 2283514 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998907257 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09380609 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998907257 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997008015 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998907257 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019997008015 Country of ref document: KR |